Amelioration of COVID-19-related cytokine storm syndrome: parallels to chimeric antigen receptor-T cell cytokine release syndrome.
作者信息
Hoiland Ryan L, Stukas Sophie, Cooper Jennifer, Thiara Sonny, Chen Luke Y C, Biggs Catherine M, Hay Kevin, Lee Agnes Y Y, Shojania Kamran, Abdulla Alym, Wellington Cheryl L, Sekhon Mypinder S
机构信息
Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver, BC, Canada.
Centre for Heart, Lung, and Vascular Health, School of Health and Exercise Sciences, University of British Columbia - Okanagan, Kelowna, BC, Canada.
出版信息
Br J Haematol. 2020 Aug;190(3):e150-e154. doi: 10.1111/bjh.16961. Epub 2020 Jul 16.
Abstract
摘要
相似文献
1
Amelioration of COVID-19-related cytokine storm syndrome: parallels to chimeric antigen receptor-T cell cytokine release syndrome.
Br J Haematol. 2020 Aug;190(3):e150-e154. doi: 10.1111/bjh.16961. Epub 2020 Jul 16.
2
Interleukin-6 blockade treatment for COVID-19 associated cytokine release syndrome in a patient with poorly controlled chronic myeloid leukaemia.
Br J Haematol. 2020 Aug;190(3):e128-e130. doi: 10.1111/bjh.16901. Epub 2020 Jun 26.
3
The COVID-19 Cytokine Storm; What We Know So Far.
Front Immunol. 2020 Jun 16;11:1446. doi: 10.3389/fimmu.2020.01446. eCollection 2020.
4
Cytokine Storm Drugs Move from CAR T to COVID-19.
Cancer Discov. 2020 Jul;10(7):OF8. doi: 10.1158/2159-8290.CD-ND2020-008. Epub 2020 May 5.
5
Immunosuppression during the COVID-19 pandemic in neuromyelitis optica spectrum disorders patients: A new challenge.
Mult Scler Relat Disord. 2020 Jun;41:102097. doi: 10.1016/j.msard.2020.102097. Epub 2020 Apr 5.
6
Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome.
Eur Respir J. 2020 Oct 1;56(4). doi: 10.1183/13993003.03006-2020. Print 2020 Oct.
7
Role of Interleukin-6 in Lung Complications in Patients With COVID-19: Therapeutic Implications.
In Vivo. 2020 Jun;34(3 Suppl):1589-1592. doi: 10.21873/invivo.11947.
8
Immunologic Features in Coronavirus Disease 2019: Functional Exhaustion of T Cells and Cytokine Storm.
J Clin Immunol. 2020 Oct;40(7):974-976. doi: 10.1007/s10875-020-00824-4. Epub 2020 Jul 10.
9
Rapid resolution of cytokine release syndrome and favorable clinical course of severe COVID-19 in a kidney transplant recipient treated with tocilizumab.
Kidney Int. 2020 Aug;98(2):508-509. doi: 10.1016/j.kint.2020.05.022. Epub 2020 Jun 4.
10
Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19.
Int Immunopharmacol. 2020 Sep;86:106749. doi: 10.1016/j.intimp.2020.106749. Epub 2020 Jul 1.
引用本文的文献
1
Network Pharmacology and Experiment Verification-Based Strategy for Exploring the Mechanisms of Shuqing Granule in the Treatment of COVID-19.
Pharmaceuticals (Basel). 2025 Aug 18;18(8):1216. doi: 10.3390/ph18081216.
2
ABO blood group and COVID-19 severity: Associations with endothelial and adipocyte activation in critically ill patients.
PLoS One. 2025 Apr 2;20(4):e0320251. doi: 10.1371/journal.pone.0320251. eCollection 2025.
3
Immune and inflammation features of severe and critical Omicron infected patients during Omicron wave in China.
BMC Infect Dis. 2024 Aug 9;24(1):809. doi: 10.1186/s12879-024-09652-y.
4
A Computational Model of Cytokine Release Syndrome during CAR T-cell Therapy.
Adv Ther (Weinh). 2022 Oct;5(10). doi: 10.1002/adtp.202200130. Epub 2022 Aug 4.
5
Enhanced Label-Free Nanoplasmonic Cytokine Detection in SARS-CoV-2 Induced Inflammation Using Rationally Designed Peptide Aptamer.
ACS Appl Mater Interfaces. 2022 Nov 2;14(43):48464-48475. doi: 10.1021/acsami.2c14748. Epub 2022 Oct 25.
6
Reduced fixed dose tocilizumab 400 mg IV compared to weight-based dosing in critically ill patients with COVID-19: A before-after cohort study.
Lancet Reg Health Am. 2022 Jul;11:100228. doi: 10.1016/j.lana.2022.100228. Epub 2022 Mar 23.
7
Pharmaco-immunomodulatory interventions for averting cytokine storm-linked disease severity in SARS-CoV-2 infection.
Inflammopharmacology. 2022 Feb;30(1):23-49. doi: 10.1007/s10787-021-00903-x. Epub 2022 Jan 20.
8
Mini-Factor H Modulates Complement-Dependent IL-6 and IL-10 Release in an Immune Cell Culture (PBMC) Model: Potential Benefits Against Cytokine Storm.
Front Immunol. 2021 Apr 28;12:642860. doi: 10.3389/fimmu.2021.642860. eCollection 2021.
9
Treatment of COVID-19 by stage: any space left for mesenchymal stem cell therapy?
Regen Med. 2021 May;16(5):477-494. doi: 10.2217/rme-2020-0189. Epub 2021 May 14.
10
Absence of "Cytokine Storm" in Hospitalized COVID-19 Patients: A Retrospective Cohort Study.
Infect Dis Rep. 2021 Apr 19;13(2):377-387. doi: 10.3390/idr13020036.
本文引用的文献
1
Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes.
Blood Rev. 2021 Jan;45:100707. doi: 10.1016/j.blre.2020.100707. Epub 2020 May 15.
2
Cytokine Levels in the Body Fluids of a Patient With COVID-19 and Acute Respiratory Distress Syndrome: A Case Report.
Ann Intern Med. 2020 Sep 15;173(6):499-501. doi: 10.7326/L20-0354. Epub 2020 May 12.
3
Effective treatment of severe COVID-19 patients with tocilizumab.
Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975. doi: 10.1073/pnas.2005615117. Epub 2020 Apr 29.
4
Facing COVID-19 in the ICU: vascular dysfunction, thrombosis, and dysregulated inflammation.
Intensive Care Med. 2020 Jun;46(6):1105-1108. doi: 10.1007/s00134-020-06059-6. Epub 2020 Apr 28.
5
Elevated interleukin-6 and severe COVID-19: A meta-analysis.
J Med Virol. 2020 Nov;92(11):2283-2285. doi: 10.1002/jmv.25948. Epub 2020 Jun 2.
6
Clinical and immunological features of severe and moderate coronavirus disease 2019.
J Clin Invest. 2020 May 1;130(5):2620-2629. doi: 10.1172/JCI137244.
7
Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study.
BMJ. 2020 Mar 26;368:m1091. doi: 10.1136/bmj.m1091.
8
Clinical Features of 69 Cases With Coronavirus Disease 2019 in Wuhan, China.
Clin Infect Dis. 2020 Jul 28;71(15):769-777. doi: 10.1093/cid/ciaa272.
9
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.
Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
10
Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China.
Clin Infect Dis. 2020 Jul 28;71(15):762-768. doi: 10.1093/cid/ciaa248.
Zotero 插件